All News #Library
Biotech
Sanofi Completes the Acquisition of Vigil Neuroscience
06 Aug 2025 //
PRESS RELEASE
Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Ph 2 Trial
05 Jun 2025 //
GLOBENEWSWIRE
Vigil’s TREM2-Targeted Alzheimer’s Shows Early Promise
24 Jan 2025 //
BIOSPACE
Vigil Presents Vgl101 Complete Phase 1 Data And Phase 2 Ignite Trial Design
11 Sep 2023 //
PRESS RELEASE

Market Place
Sourcing Support